SABCS 2018: No Benefit to Capecitabine Following Surgery and Chemotherapy for Triple-Negative Breast Cancer
Adjuvant capecitabine disappoints in phase III trial, with one exception
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.